New PD-L1 inhibitors in non-small cell lung cancer – impact of atezolizumab
Lung Cancer: Targets and Therapy · 2017
DOI: 10.2147/lctt.s113177 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Lung Cancer: Targets and Therapy, 2017. Verfasst von Nagashree Seetharamu und 2 weiteren Autor:innen. Beteiligte Einrichtung: Monter Cancer Center, Hofstra-Northwell Health School of Medicine, Lake Success, NY, USA. Die Arbeit wurde bisher 11-mal zitiert (Crossref). Der Volltext ist frei zugänglich (Open Access, CC BY-NC 3.0).
Abstract (Originalsprache)
Kein Abstract verfügbar.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Monter Cancer Center, Hofstra-Northwell Health School of Medicine, Lake Success, NY, USA.
Zitieren
APA
Seetharamu, N., Preeshagul, I. R., & Sullivan, K. M. (2017). New PD-L1 inhibitors in non-small cell lung cancer – impact of atezolizumab. Lung Cancer: Targets and Therapy. https://doi.org/10.2147/lctt.s113177
Vancouver
Seetharamu N, Preeshagul IR, Sullivan KM. New PD-L1 inhibitors in non-small cell lung cancer – impact of atezolizumab. Lung Cancer: Targets and Therapy. 2017. doi:10.2147/lctt.s113177
BibTeX
@article{Seetharamu2017,
author = {Seetharamu, Nagashree and Preeshagul, Isabel R and Sullivan, Kevin M},
title = {New PD-L1 inhibitors in non-small cell lung cancer – impact of atezolizumab},
journal = {Lung Cancer: Targets and Therapy},
year = {2017},
doi = {10.2147/lctt.s113177}
}
EUVIMED